"Issuance of the new patent for our oncology preclinical aPKCi inhibitor pipeline is an important part of our development strategy," said Jed Latkin, CEO of Windtree Therapeutics. "We will continue with our intellectual property work to expand our patent portfolio in key markets throughout the world." About aPKCi inhibitor The Company's oncology aPKCi inhibitor is a novel, first in class drug candidate WARRINGTON, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company ...